Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
GFC Life Science Co., Ltd. is a South Korean biotechnology company that develops and manufactures innovative bio-materials for the cosmetics and medical aesthetics industries. Founded in 2002 and listed on the KOSDAQ in 2025, the company utilizes proprietary platforms such as Hybrid-Exotech and Boosting Exo-Tech to produce high-purity plant-derived and microbial exosomes. Its business model integrates raw material R&D, manufacturing, and clinical evaluation services through its subsidiary, the Korea Dermatology Research Institute. Recently, GFC Life Science has expanded into the medical aesthetics market with the launch of its GFCCELL Luxe Filler, a hyaluronic acid-based product line, and various exosome-based skin boosters. The company is actively pursuing global expansion, targeting distribution in over 30 countries across Europe, the Middle East, and Asia.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on GFC Life Science.